You are being redirected to another site.
The MDS Use of Botulinum Neurotoxin (BoNT) For Cranial Movement Disorders (CMD) course will provide a practical, case-based presentation, bringing a rational approach for treating CMD with BoNT injections. The first part of the course presents general information about blepharospasm, hemifacial spasm and oromandibular dystonia, including a treatment algorithm. The second part of the course shows BoNT injection techniques into specific muscles affected by blepharospasm, hemifacial spasm and oromandibular dystonia.
Shivam Om Mittal, MD - Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
This MDS Interactive module provides learners with information regarding the approach for treating cranial movement disorders (CMD) with botulinum neurotoxin (BoNT) injections.
Upon completion of this activity, learners will be able to:
1. Recognize common presentations of CMD (blepharospasm, hemifacial spasm, oromandibular dystonia)2. Understand the muscles involved in CMD and understand the rationale for muscle selection for BoNT treatment3. Implement a decision-making strategy for treating patients with CMD, including: a) choosing those who may benefit from electromyographic or ultrasound guidance; b) choosing the BoNT type; and c) listing the dosing, injection site and adverse effects
This activity is intended for students, residents, primary care providers, internists, allied health, non-neurology specialists, and industry who have limited to no movement disorder experience.
Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed in the Accreditation Statement, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.
All individuals in control of content for this activity are required to disclose all financial relationships with ineligible companies (as defined by the ACCME) over the last 24 months. Disclosure information is available below. All relevant financial relationships have been mitigated in advance of this program.Shivam Om Mittal: AuthorConsultant: AbbVie, Allergan, EverPharmaSpeaker: AbbVie, EverPharmaRafael Zuzuarregui: ReviewerNothing to Disclose
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The International Parkinson and Movement Disorder Society designates this education activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.2. Compatible with Windows PC and MAC (256 MB of RAM or higher)3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher4. Adobe Flash Player 12.0 (or higher).5. Adobe Reader to print certificate.
MDS staff members involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.